Exact Sciences (EXAS) Competitors $48.92 -0.59 (-1.18%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EXAS vs. ALNY, BIIB, UTHR, INCY, BMRN, NBIX, EXEL, RGEN, HALO, and MDGLShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings. Does the media favor ALNY or EXAS? In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Exact Sciences. MarketBeat recorded 43 mentions for Alnylam Pharmaceuticals and 31 mentions for Exact Sciences. Alnylam Pharmaceuticals' average media sentiment score of 0.52 beat Exact Sciences' score of 0.49 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 20 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 10 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Is ALNY or EXAS more profitable? Exact Sciences has a net margin of -7.95% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Exact Sciences -7.95%-6.17%-2.98% Which has more risk and volatility, ALNY or EXAS? Alnylam Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Do analysts prefer ALNY or EXAS? Alnylam Pharmaceuticals presently has a consensus target price of $299.48, indicating a potential upside of 18.61%. Exact Sciences has a consensus target price of $72.06, indicating a potential upside of 45.54%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72Exact Sciences 0 Sell rating(s) 1 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.95 Does the MarketBeat Community favor ALNY or EXAS? Alnylam Pharmaceuticals received 158 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.20% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.13% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes114376.20% Underperform Votes35723.80% Exact SciencesOutperform Votes98573.13% Underperform Votes36226.87% Do institutionals and insiders hold more shares of ALNY or EXAS? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Exact Sciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.4% of Exact Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, ALNY or EXAS? Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B14.54-$278.16M-$2.17-116.36Exact Sciences$2.50B3.67-$204.15M-$1.17-42.32 SummaryAlnylam Pharmaceuticals and Exact Sciences tied by winning 9 of the 18 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.16B$3.20B$5.80B$9.11BDividend YieldN/A21.14%5.28%3.98%P/E Ratio-42.3214.8225.2618.83Price / Sales3.67178.97473.04119.70Price / Cash2,914.15379.5545.1138.19Price / Book2.855.117.675.13Net Income-$204.15M-$22.21M$3.18B$245.96M7 Day Performance0.41%-1.09%-0.50%-0.89%1 Month Performance-8.75%3.29%1.84%-0.51%1 Year Performance-21.77%18.67%18.75%16.50% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.671 of 5 stars$48.92-1.2%$72.06+47.3%-21.1%$9.07B$2.76B-8.796,600Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageALNYAlnylam Pharmaceuticals4.5256 of 5 stars$256.45-3.2%$299.43+16.8%+68.7%$33.08B$1.83B-97.882,100Analyst ForecastInsider TradeBIIBBiogen4.7769 of 5 stars$137.33-0.8%$211.96+54.3%-37.5%$20.01B$9.84B12.417,570Analyst ForecastUTHRUnited Therapeutics4.4129 of 5 stars$370.58+0.0%$382.08+3.1%+71.5%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5814 of 5 stars$70.42+0.6%$75.59+7.3%+21.4%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9364 of 5 stars$64.85+0.7%$94.20+45.3%-22.5%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNBIXNeurocrine Biosciences4.9754 of 5 stars$115.02-1.6%$166.90+45.1%-12.5%$11.65B$2.36B34.961,400Analyst DowngradeAnalyst RevisionGap UpEXELExelixis4.6803 of 5 stars$35.00+1.5%$37.24+6.4%+70.1%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeGap UpRGENRepligen4.3262 of 5 stars$146.92+0.5%$182.91+24.5%-18.6%$8.23B$638.76M-397.071,783Earnings ReportAnalyst ForecastNews CoverageHALOHalozyme Therapeutics4.5001 of 5 stars$58.29-0.5%$60.89+4.5%+59.6%$7.42B$829.25M19.30390Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMDGLMadrigal Pharmaceuticals3.3531 of 5 stars$337.20-4.1%$351.67+4.3%+52.8%$7.35BN/A-13.4490 Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EXAS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
